- $1.32bn
- $931.80m
- $682.16m
- 61
- 81
- 72
- 83
Annual income statement for Novavax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 476 | 1,146 | 1,982 | 984 | 682 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 1,079 | 640 | 480 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 892 | 2,833 | 2,627 | 1,550 | 931 |
| Operating Profit | -417 | -1,687 | -645 | -567 | -249 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -418 | -1,715 | -654 | -543 | -177 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -418 | -1,744 | -658 | -545 | -187 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -418 | -1,744 | -658 | -545 | -187 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -418 | -1,744 | -658 | -545 | -187 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.27 | -23.4 | -8.42 | -5.32 | -1.38 |